Home Meeting notice Ascendis Health: Notice of Special General Meeting and New Shareholder Demands

Ascendis Health: Notice of Special General Meeting and New Shareholder Demands

0






Notice of Special General Meeting and New Shareholder Demands

 Ascendis Health Limited
 (Registration number 2008/005856/06)
 (Incorporated in the Republic of South Africa)
 Share code: ASC
 ISIN: ZAE000185005
 ("Ascendis Health" or "the Company")


                  NOTICE OF SPECIAL GENERAL MEETING AND NEW SHAREHOLDER DEMANDS


Shareholders are referred to the announcement published on SENS on 17 March 2022 in which they were advised
that the Company had received a demand in terms of section 61(3) of the Companies Act, No. 71 of 2008, as
amended ("the Companies Act"), read with clause 20.1.3 of the Company's Memorandum of Incorporation from
Alpvest Equities Proprietary Limited, Dendrobium Capital Proprietary Limited and Andre Carl Neethling
("Neethling Consortium Demand") in their capacities as shareholders of the Company, to call a general meeting
of shareholders ("Special General Meeting") to consider the appointment of Amaresh Chetty, Bharti Harie and
Carl Neethling as non-executive directors of the Company.

Shareholders are advised that in terms of the Company's senior financing arrangements, any change to the board
of directors of the Company ("the Board") which has not received the prior written approval of the agent (acting
on behalf of the lenders) may trigger a cancellation of the debt facilities and may result in such debt facilities
becoming immediately due and payable. The Lenders, based on their preliminary analysis, have indicated that
they do not intend to approve the proposed Board changes contemplated in the Neethling Consortium Demand.

The Board does not support these proposed appointments.

Shareholders are further advised that, on 31 March 2022, the Company received a written request in terms of
section 61(3) of the Companies Act from a different group of shareholders who together hold Ascendis Health
shares representing more than 10% of the Company's voting rights, to include resolutions to appoint Maki
Modisakeng, Samuel Miller and Francois Theron as independent non-executive directors of the Company in terms
of article 26 of the Company's Memorandum of Incorporation ("the Additional Demand").

Resolutions in respect of the Additional Demand will be included in the Notice of Special General Meeting.

Shareholders are advised that the Board supports the proposed appointments of these candidates. In addition,
based on their preliminary analysis, the Lenders have indicated that they support these candidates nominations.

The purpose of the Special General Meeting is to put to shareholders for consideration the shareholder proposed
resolutions to appoint Maki Modisakeng, Samuel Miller and Francois Theron, Amaresh Chetty, Bharti Harie and
Carl Neethling as non-executive directors of the Company.


1.   Notice of Special General Meeting

Notice is hereby given of a Special General Meeting to be held at 10:00 on Wednesday, 11 May 2022 which will
be conducted entirely by electronic participation as contemplated in section 63(2)(a) of the Companies Act.

The notice of Special General Meeting has been distributed to shareholders today, Thursday, 31 March 2022.

 a. The salient details of the Special General Meeting are set out below.


                                                                                                                1
                                                                                                              2022
 Record date for determining those shareholders entitled to receive the notice of                 Friday, 25 March
 Special General Meeting
 Last day to trade in order to be eligible to participate in and vote at the Special General       Tuesday, 3 May
 Meeting
 Record date (for voting purposes at the Special General Meeting)                                   Friday, 6 May
 Special General Meeting convened for 10:00                                                    Wednesday, 11 May

2.   Court Application

The Company holds the view that the Neethling Consortium Demand falls to be set aside in terms of section 61(5)
of the Companies Act, and therefore is in the process of applying to the High Court to set aside the Demand. In
terms of section 61(5) of the Companies Act:
"(5) A company, or any shareholder of the company, may apply to a court for an order setting aside a demand
made in terms of subsection (3) on the grounds that the demand is frivolous, calls for a meeting for no other
purpose than to reconsider a matter that has already been decided by the shareholders, or is otherwise vexatious"
Notwithstanding the intended High Court application, in terms of the Listings Requirements of the JSE Limited
("Listings Requirements"), the Company is still obliged to give notice of a meeting within 10 business days from
the date of the Demand to call a shareholder's meeting unless the JSE decides otherwise. The JSE has not decided
otherwise, and the Company is therefore obliged to comply with the JSE Listing Requirements.

Accordingly, this notice is given on the condition that the High Court does not set aside the Demands. If the High
Court sets aside the Demands this fact will be communicated to shareholders and this Notice will be withdrawn.


31 March 2022
Bryanston

Sponsor
Questco Corporate Advisory Proprietary Limited




                                                                                                                 2

Date: 31-03-2022 05:33:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Warning

Ascendis Health Ltd. published this content on March 31, 2022 and is solely responsible for the information contained therein. Distributed by publicunedited and unmodified, on Mar 31, 2022 5:05:05 PM UTC.

Public now 2022

All news about ASCENDIS HEALTH LIMITED

Sales 2021 2,229 million
154 million
154 million
Net income 2021 -1,091M
-75.3M
-75.3M
Net debt 2021 6,613 million
457M
457M
PER 2021 ratio -0.26x
2021 performance
Capitalization 367M
25.4 million
25.4 million
EV / Sales 2020 3.28x
EV / Sales 2021 3.09x
# of employees
Floating 42.3%

Chart ASCENDIS HEALTH LIMITED


Duration :

Period :




Ascendis Health Limited Technical Analysis Chart |  MarketScreener

Trending Technical Analysis ASCENDIS HEALTH LIMITED

Short term Middle term Long term
Tendencies Bullish Neutral Neutral



Evolution of the income statement